Non-HFE-related hemochromatosis

Non-HFE-related hemochromatosis refers to a group of hereditary iron overload disorders caused by mutations in genes other than HFE, the gene responsible for the most common (classical) form of hereditary hemochromatosis. This category encompasses several distinct genetic subtypes, including hemochromatosis type 2A (caused by mutations in HJV/hemojuvelin), type 2B (caused by mutations in HAMP/hepcidin), type 3 (caused by mutations in TFR2/transferrin receptor 2), and type 4 (caused by mutations in SLC40A1/ferroportin, also known as ferroportin disease). All of these conditions share the common feature of excessive iron absorption and deposition in various organs, but they differ in their genetic basis, inheritance pattern, age of onset, and clinical severity. The body systems most affected include the liver (leading to hepatomegaly, fibrosis, and cirrhosis), the heart (cardiomyopathy and heart failure, particularly in juvenile forms), the endocrine system (diabetes mellitus, hypogonadism, hypothyroidism), the joints (arthropathy), and the skin (hyperpigmentation). Juvenile hemochromatosis (types 2A and 2B) tends to present in the first to third decades of life with severe iron loading, prominent cardiomyopathy, and hypogonadotropic hypogonadism, while types 3 and 4 generally present later in adulthood with a clinical picture more similar to classical HFE hemochromatosis. Ferroportin disease (type 4) is unique in that it follows autosomal dominant inheritance and may present with preferential iron loading in macrophages (reticuloendothelial cells) rather than hepatocytes, depending on the specific mutation. Diagnosis is based on elevated serum ferritin and transferrin saturation, confirmed by genetic testing. Treatment primarily involves therapeutic phlebotomy to reduce iron stores, which can prevent or reverse organ damage if initiated early. In ferroportin disease, tolerance to phlebotomy may be reduced, and treatment must be carefully monitored. Iron chelation therapy may be considered in patients who cannot tolerate phlebotomy. Early diagnosis and treatment are critical, especially in juvenile forms, to prevent irreversible cardiac and endocrine complications.

Common questions about Non-HFE-related hemochromatosis